Team Qld

Invest in the future

Come to Queensland, launch-pad to the Asia- Pacific healthcare market

Australia’s life sciences sector has doubled in size since 2017, with 2,900+ life sciences organisations, 1,600+ of which are biotech and medtech companies.

The sector has a total value of over A$250 billion and employs approximately 350,000 people across Australia.

Australia’s high-quality and innovative healthcare system is envied around the world and supports a world-class medical research sector.

The Gardasil® human papillomavirus (HPV) vaccine for the prevention of cervical cancer was developed in Queensland, Australia.

The Australian Government provides support at each phase of the innovation pathway, including:

•  The A$24.83 billion Medical Research Future Fund to address emerging health needs.
•  The A$15 billion National Reconstruction Fund for manufacturing, with A$1.5 billion earmarked for medical manufacturing.
•  The A$501.25 million Biomedical Translation Fund, which supports biomedical research commercialisation.
•  A Research and Development Tax Incentive, which provides a tax offset of up to 43.5% on eligible R&D expenditure.

The Queensland Government is open for business and supporting the development of priority industries with a Sovereign Industry Development Fund, which supports strategic partnership opportunities to accelerate industry development.

Queensland is a preferred destination for investors seeking strategic biomedical partnerships. In addition, Queensland’s location as a launch-pad to the fast-growing Asia-Pacific healthcare market offers aligned time zones and established trade links, providing international partners seamless access to high-growth markets.

International biomedical companies are invited to establish and expand their operations in Queensland, leveraging strategic government investment, resilient supply chains and a highly skilled workforce to build sovereign capability and access global markets from a stable and innovative jurisdiction.

As Queensland prepares to welcome the world for the 2032 Olympic and Paralympic Games, it’s time for international investors to put themselves in a win–win position and choose Queensland as their preferred location.

Learn more about Queensland and our biomedical sector by joining us at AusBiotech 2026.

Queensland’s biomedical sector

Strong biomedical foundation

• Internationally recognised scientific capabilities
• State-of-the-art research infrastructure equipped with cutting-edge technologies and expertise
• Statewide quaternary and tertiary care hospitals, enabled by Australia’s largest integrated electronic Medical Record (ieMR)
• Highly skilled workforce, with access to world-class training

The place to be for international pharmaceutical and medtech companies

• Global players such as US medtech giant Stryker and global healthcare and pharmaceutical company Sanofi (Translational Science Hub) have established a strong R&D presence in Queensland.
• Thermo Fisher Scientific, Cook Medical, Viatris and Baxter Healthcare have also chosen to locate in Queensland

Globally connected clinical trial network

• Comprehensive clinical trial ecosystem across public and private providers, trial phases and therapeutic areas
• Growing biomanufacturing capability to support clinical trials
• Quality: Globally accepted data
• Cost: 43.5% cash rebate through the R&D Tax Incentive
• Speed: Rapid trial start-up and streamlined regulatory pathway through the Clinical Trial Notification (CTN) Scheme
• Geographically dispersed and diverse patient population
• Potential for year-round trials across tropical and subtropical climate zones

Proven collaborative approach

• Team Queensland: Triple helix approach, with government, academia and industry working together
• Agile and innovative models for investment and integration into the local biomedical ecosystem
• Integrated centres for healthcare services, research, translation, education and training

“We have been seduced from day one by the quality of the science that we saw here, but also very much seduced by the ‘one Queensland team’ approach. We’re also coming here to Queensland because of the vision of the government of Queensland and the universities, working together with the ambition to make Queensland a global biomedical hub.”

Dr Jean-Francois Toussaint, Global Head of Vaccine Research and Development, Sanofi